CN112336833A

CN112336833A - A Chinese medicinal composition for treating hemorrhagic eye diseases, and its preparation method

Info

Publication number: CN112336833A
Application number: CN202010541616.5A
Authority: CN
Inventors: 周燕英
Original assignee: Individual
Current assignee: Individual
Priority date: 2020-06-15
Filing date: 2020-06-15
Publication date: 2021-02-09

Abstract

The invention discloses a traditional Chinese medicine composition for treating hemorrhagic eye diseases and a preparation method thereof, and relates to the technical field of traditional Chinese medicines. The traditional Chinese medicine is mainly used for improving eyesight, promoting blood circulation, removing blood stasis, promoting and improving retinal blood circulation, dredging blood vessels, increasing blood supply, improving the conditions of tissue ischemia and hypoxia, and promoting bleeding, edema, exudation and absorption of fibroplasia organization tissues, thereby achieving the effect of treatment.

Description

A Chinese medicinal composition for treating hemorrhagic eye diseases, and its preparation method

Technical Field

The invention relates to the technical field of traditional Chinese medicines, in particular to a traditional Chinese medicine composition for treating hemorrhagic eye diseases and a preparation method thereof.

Background

The hemorrhagic eye diseases are caused by macular degeneration, retinal vein occlusion, diabetic retinopathy and the like. Anti-vascular endothelial growth factor drugs (anti-VE F drugs for short) approved by the United states food and drug administration are obtained in 2 months in 2004 and become first-line drugs for colon or rectal metastatic cancer, anti-VE F drugs are also approved for treating hemorrhagic eye diseases in ophthalmology in 2006, breakthrough progress is made, and a new medical prize in the United states is obtained.

However, the use of anti-VE class F drugs in ophthalmology has the following drawbacks:

1. the treatment range is small.

The application range of the VE part resisting F medicines is only neovascular (wet) macular degeneration, macular edema caused by retinal vein obstruction and macular edema caused by diabetes, and the VE part resisting F medicines cannot absorb vitreous hemorrhage to cause the condition of subretinal effusion;

2. the operation difficulty is high and the sanitary requirement is high.

The VE resisting F medicine needs to be injected into the eyeball through a small operation of eyeball puncture, a specific environment (sterile disinfection) and specific personnel (ophthalmologists) need to be configured, and antibiotic eye drops need to be used before and after the operation;

3. adverse reactions and complications exist.

Slight redness, ocular pain, subconjunctival hemorrhage, serious intrabulbar infection, intrabulbar hemorrhage, and rhegmatogenous retinal detachment, and serious complications can cause visual function loss and even blindness;

4. the cost is high.

The therapeutic effect of the existing VE resistant F medicines can only be maintained for 1.5 months at the longest, and injection treatment needs to be performed at regular time, however, the price of each needle of the VE resistant F medicines is different from 8000 yuan and 10000 yuan, and the charges of different hospitals are different.

Disclosure of Invention

Aiming at the problem in practical application, the invention aims to provide a traditional Chinese medicine composition for treating hemorrhagic eye diseases and a preparation method thereof, and the specific scheme is as follows:

the traditional Chinese medicine composition for treating the hemorrhagic eye diseases comprises the following traditional Chinese medicines by weight:

20 parts of prepared rhizome of rehmannia, 10 parts of angelica, 10 parts of ligusticum wallichii, 10 parts of red paeony root, 10 parts of safflower, 10 parts of seaweed, 10 parts of kelp, 20 parts of salvia miltiorrhiza, 15 parts of raw grass, 15 parts of raw abalone shell, 20 parts of butterflybush flower, 20 parts of semen cuscutae, 10 parts of rhizoma sparganii, 10 parts of curcuma zedoary, 11-15 parts of peach kernel and 21-25 parts of medlar.

Further preferably, the traditional Chinese medicine composition for treating hemorrhagic eye diseases is prepared from the following traditional Chinese medicines by weight: 20 parts of prepared rhizome of rehmannia, 10 parts of angelica, 10 parts of ligusticum wallichii, 10 parts of red paeony root, 10 parts of safflower, 10 parts of seaweed, 10 parts of kelp, 20 parts of salvia miltiorrhiza, 15 parts of raw grass, 15 parts of raw abalone shell, 20 parts of butterflybush flower, 20 parts of semen cuscutae, 10 parts of rhizoma sparganii, 10 parts of curcuma zedoary, 11-12 parts of peach kernel and 21-22 parts of medlar.

Further preferably, the traditional Chinese medicine composition for treating hemorrhagic eye diseases is prepared from the following traditional Chinese medicines by weight: 20 parts of prepared rhizome of rehmannia, 10 parts of angelica, 10 parts of ligusticum wallichii, 10 parts of red paeony root, 10 parts of safflower, 10 parts of seaweed, 10 parts of kelp, 20 parts of salvia miltiorrhiza, 15 parts of raw grass, 15 parts of raw abalone shell, 20 parts of butterflybush flower, 20 parts of semen cuscutae, 10 parts of rhizoma sparganii, 10 parts of curcuma zedoary, 11 parts of peach kernel and 21 parts of medlar.

A preparation method of a traditional Chinese medicine composition for treating hemorrhagic eye diseases comprises the following steps:

step 1, separately drying prepared rehmannia root, Chinese angelica, szechuan lovage rhizome, red paeony root, safflower, seaweed, kelp, salvia miltiorrhiza, raw grass, raw sea-ear shell, pale butterflybush flower, south dodder seed, common burreed rhizome, zedoary, peach kernel and medlar to reduce the water content in each traditional Chinese medicine to 6-8 wt%;

step 2, after drying, taking 20 parts of prepared rehmannia root, 10 parts of Chinese angelica, 10 parts of ligusticum wallichii, 10 parts of red paeony root, 10 parts of safflower, 10 parts of seaweed, 10 parts of kelp, 20 parts of salvia miltiorrhiza, 15 parts of raw grass, 15 parts of raw abalone shell, 20 parts of butterflybush flower, 20 parts of semen cuscutae, 10 parts of rhizoma sparganii, 10 parts of curcuma zedoary, 11-15 parts of peach kernel and 21-25 parts of medlar according to weight, putting the mixture into a medicine tank, injecting 1250 milliliters of pure water into the medicine tank, stirring and mixing the traditional Chinese medicines and the water, and soaking for 35 minutes;

step 3, after soaking, placing the medicine tank on a heating device, firstly heating the medicine tank at the heating temperature of 60-80 ℃ until water is boiled, and then continuously heating the medicine tank at the heating temperature of 40-50 ℃ until the medicine liquid is concentrated to 90-110 ml, so as to finish heating;

and 4, filtering the decoction to remove the dregs of a decoction, and taking the decoction.

Compared with the prior art, the invention has the following beneficial effects:

the treatment principle of the traditional Chinese medicine composition is as follows: hemorrhagic ophthalmopathy such as macular degeneration, retinal vein occlusion and the like all have retinal blood circulation obstacles in different degrees, cause insufficient blood supply of tissues and generate abnormal blood vessels, thereby causing pathological changes. The traditional Chinese medicine is mainly used for improving eyesight, promoting blood circulation, removing blood stasis, promoting and improving retinal blood circulation, dredging blood vessels, increasing blood supply, improving the conditions of tissue ischemia and hypoxia, and promoting bleeding, edema, exudation and absorption of fibroplasia organization tissues, thereby achieving the effect of treatment.

Drawings

FIG. 1 is a B-ultrasonic image of the right eye of HU-somewhat 2001.9.10 in example 1;

FIG. 2 is a fluorescence photograph of the right eye of a moustache 2001.9.10 from example 1;

FIG. 3 is a B-ultrasonic image of the right eye of another 2007.4.30 of example 1;

FIG. 4 is a fluorescence photograph of the right eye of a moustache 2008.1.2 from example 1;

FIG. 5 is an OCT test chart of example 2 Gong's 2005.9.6;

FIG. 6 is an OCT test chart of example 2 Gong's 2005.9.20;

FIG. 7 is a schematic view of the example 2 Gong's 2005.12.26 binocular B ultrasound;

FIG. 8 is a fluorescence micrograph of 2006.1.10 Gong from example 2.

FIG. 9 is an OCT test chart of example 2 Gong's 2006.12.25;

FIG. 10 is a fluorescence micrograph of 2006.12.25 Gong from example 2;

FIG. 11 is an OCT test chart of example 2 Gong's 2007.3.22;

FIG. 12 is an OCT test chart of example 2 Gong's 2007.5.15;

FIG. 13 is an OCT test chart of example 2 Gong's 2007.7.25;

FIG. 14 is an OCT test chart of example 2 Gong's 2007.12.27;

FIG. 15 is a fluorescence micrograph of 2008.1.15 Gong from example 2;

FIG. 16 is an OCT test chart of example 2 Gong's 2008.3.13;

FIG. 17 is an OCT test chart of example 2 Gong's 2008.10.16;

FIG. 18 is an OCT test chart of example 2 Gong's 2008.11.27;

FIG. 19 is an OCT test chart of example 2 Gong's 2009.1.9;

FIG. 20 is an OCT test chart of example 2 Gong's 2009.9.28;

FIG. 21 is a fluorescence micrograph of 2010.3.15 Gong from example 2;

FIG. 22 is an OCT test chart of example 2 Gong's 2010.3.25;

FIG. 23 is an OCT test chart of example 2 Gong's 2011.3.30;

FIG. 24 is a fluorescence micrograph of 2011.6.14 Gong from example 2;

FIG. 25 is a diagnostic graph of 2011.6.14ICGA for Gong's disease in example 2;

FIG. 26 is an OCT test chart of example 2 Gong's 2011.12.28;

FIG. 27 is a fluorescence micrograph of 2012.1.3 Gong from example 2;

FIG. 28 is a fluorescence micrograph of 2012.10.11 Gong from example 2;

FIG. 29 is a graph of OCT examination of example 2 Gong's certain review;

FIG. 30 is an OCT test chart of example 2 Gong's 2012.10.23;

FIG. 31 is an OCT test chart of example 2 Gong's 2012.12.5;

FIG. 32 is a diagnostic graph of 2012.12.5ICGA for Gong's disease in example 2;

FIG. 33 is an OCT test chart of example 2 Gong's 2013.12.4;

FIG. 34 shows the scan of 2013.12.17FA at Gong for example 2.

Detailed Description

The present invention will be described in further detail with reference to examples and drawings, but the present invention is not limited to these examples.

Taking prepared rehmannia root, Chinese angelica, szechuan lovage rhizome, red paeony root, safflower, seaweed, kelp, salvia miltiorrhiza, raw grass, raw abalone shell, pale butterflybush flower, south dodder seed, common burreed rhizome, zedoary, peach seed and medlar, and drying the traditional Chinese medicines separately to reduce the water content in each traditional Chinese medicine to 8 wt%.

Example 1

After drying, taking 20 parts of prepared rehmannia root, 10 parts of angelica, 10 parts of ligusticum wallichii, 10 parts of red paeony root, 10 parts of safflower, 10 parts of seaweed, 10 parts of kelp, 20 parts of salvia miltiorrhiza, 15 parts of raw grass, 15 parts of raw abalone shell, 20 parts of butterflybush flower, 20 parts of semen cuscutae, 10 parts of rhizoma sparganii, 10 parts of curcuma zedoary, 11 parts of peach kernel and 21 parts of medlar by weight, putting the mixture into a casserole medicine pot, injecting 1250 milliliters of pure clean water into the medicine pot, stirring and mixing the traditional Chinese medicines with the water, and soaking for 35 minutes.

After soaking, the earthenware pot is placed on a gas stove, the pot is heated by medium fire at 60-80 ℃ until water is boiled, the pot is further heated by small fire at 40-50 ℃ until the pot is concentrated to 100 ml of decoction, the decoction is filtered, and the decoction is taken.

The administration mode is as follows: twice daily, preferably at ten and a half am and four and a half pm.

Example 2

After drying, taking 20 parts of prepared rehmannia root, 10 parts of angelica, 10 parts of ligusticum wallichii, 10 parts of red paeony root, 10 parts of safflower, 10 parts of seaweed, 10 parts of kelp, 20 parts of salvia miltiorrhiza, 15 parts of raw grass, 15 parts of raw abalone shell, 20 parts of butterflybush flower, 20 parts of semen cuscutae, 10 parts of rhizoma sparganii, 10 parts of curcuma zedoary, 12 parts of peach kernel and 22 parts of medlar by weight, putting the mixture into a casserole medicine pot, injecting 1250 milliliters of pure clean water into the medicine pot, stirring and mixing the traditional Chinese medicines with the water, and soaking for 35 minutes.

Example 3

After drying, taking 20 parts of prepared rehmannia root, 10 parts of angelica, 10 parts of ligusticum wallichii, 10 parts of red paeony root, 10 parts of safflower, 10 parts of seaweed, 10 parts of kelp, 20 parts of salvia miltiorrhiza, 15 parts of raw grass, 15 parts of raw abalone shell, 20 parts of butterflybush flower, 20 parts of semen cuscutae, 10 parts of rhizoma sparganii, 10 parts of rhizoma zedoariae, 15 parts of peach kernel and 25 parts of medlar by weight, putting the mixture into a casserole medicine pot, injecting 1250 milliliters of pure water into the medicine pot, stirring and mixing the traditional Chinese medicines with the water, and soaking for 35 minutes.

In order to better verify the efficacy of the present invention, the following treatment examples are combined to further illustrate the therapeutic effect of the Chinese medicinal composition for treating hemorrhagic eye diseases.

Example 1

Hu da, main, 54 years old. 2001.9.10 the patients can be diagnosed before one day because of sudden drop of right eye vision and floating shadow, without obvious inducement, and the original vision of both eyes is the same, without disease history of systemic diseases. And (4) checking: the vision of the right eye is 0.3, the anterior segment (-) of the right eye, the vitreous body is obviously turbid, the fundus is seen in the temporal side of the macula lutea hemorrhage, and the foveal reflex (-) of the macula lutea is diagnosed as possible age-related macular degeneration. 0.9 of left eye vision, no obvious abnormality in anterior segment of eye and fundus.

As shown in fig. 1, right eye B-mode: A1.54X 6.4mm hemispherical bulge is seen in the superolateral equatorial part of the temporal side of the right eye, protruding into the vitreous, where the superolateral vitreous is in adhesion with the retina.

As shown in fig. 2, right eye fluorography: the temporal side of the retina of the right eye is covered by a large fluorescent screen, is located under the blood vessel and is diagnosed as subretinal hemorrhage of the right eye.

The patient goes to a special hospital and asks experts for consultation, is diagnosed as macular degeneration (early stage) of the right eye after reviewing the fluorescence radiography, and is treated by combining Chinese medicines and western medicines. In the embodiment, the western medicines are dibazole, vitamin C, vitamin E, multi-vitamin tablets and coenzyme Q10.

2001.10.25 for double diagnosis, the right eye has 0.5 vision, and the fundus hemorrhage is obviously absorbed and diminished.

2001.11.19 and the vision of right eye is 0.9, the eyeground hemorrhage is completely absorbed, large yellow-white scar is left, and the foveal reflex (+) of the macula is obtained.

2001.11.26 the right eye was rechecked for unchanged vision and fundus.

As shown in fig. 3, 2007.4.30 patients were again reviewed for unchanged right eye vision and fundus, for B-mode: vitreous opacity and posterior vitreous detachment in the right eye.

As shown in figure 4, 2008.1.2 shows that the visual acuity and the condition of the eyes are unchanged and the fluorescence contrast is reviewed, the regression time of the retinal artery and vein filling of the right eye is approximately normal, the fluorescence staining of the 4PD range is seen on the early temporal side, the fluorescence abnormality is not seen on the later stage, and the fluorescence staining of the temporal side is still seen, and the conclusion is that: the right eye is a retinal organized lesion (old) that has not recurred to date.

Example 2

Gong Yi and Yun Nei, 38 years old. 2005.9.6 the patient will see the doctor two days before the eye will have no obvious incentive for vision loss. The diagnosis is the myopia of the left eye and the macular degeneration. The eye had a history of-4, 5DS myopia. There is no history of systemic disease. The right eye feels good vision from the young, and the electric wire is touched carelessly when playing, so that the current is not seen when the vision is stopped after the right eye passes through the right limb, and is manually operated from 1.5 to the front of the eye, and the vision is not recovered after the vision is stopped.

The patient comes to a clinic before 2005.9.15, and has self-glasses vision, wherein the vision is that the patient is manually operated (cannot be corrected) in front of the right eye, 0.2 of the left eye (1.0 of the original glasses), the anterior segment (-) of the two eyes, and the right fundus is not obviously abnormal, but the macula lutea is concavely reflected (-). The macula at the bottom of the left eye bleeds, oozes, and is accompanied by edema. Diagnosed as myopia in the left eye, macular degeneration. The Chinese and western medicine combination therapy is provided. In the embodiment, the western medicines are dibazole, vitamin C, vitamin E, multi-vitamin tablets and coenzyme Q10.

As shown in fig. 5, 2005.9.6OCT examines the macula: the RPE layer bulges. No fluorescence imaging was performed.

As shown in fig. 6, 2005.9.20 review OCT. The patient still did not agree to fluorography.

As shown in fig. 7, 2005.12.26 binocular B-mode: left eye AL 25.53mm, double eye vitreous opacity, right eye vitreous posterior detachment. Can be used for treating macular hemorrhage, exudation, edema and slow hemorrhage absorption of left eye. Complete absorption does not occur until 2005.12 has bleeding. When wearing glasses, the vision reaches 0.6, and the center of the object has a black shadow. Patients were instructed to fluorography by consent.

As shown in fig. 8, 2006.1.10 fluorescence contrast: the papilla of the left eye shows arc-shaped spots, and the macula part shows high fluorescence in the early stage, has fluorescence enhancement along with time and has fluorescence leakage. And (4) conclusion: left eye macular CNV, ametropia, suggested OCT, optometry.

As shown in fig. 9, 2006.12.25 recheck the OCT condition improved.

As shown in fig. 10, 2006.12.25 review the fluorescence contrast.

As shown in FIG. 11, 2007.3.22 patients with diarrhea were blurry in the left eye for two days, and the left eye was examined for macular degeneration. When the OCT is rechecked, the vision reaches 0.5 after bleeding and absorption.

As shown in FIG. 12, 2007.5.15 patient feels blurred in left eye due to cold, and then examined for macula and bleeding, and examined for OCT again.

As shown in FIG. 13, the OCT is reviewed later by 2007.7.25 that the patient bleeds twice again due to diarrhea and cold (i.e., bleeds four times after the first visit bleeding was absorbed).

As shown in fig. 14, 2007.12.27 review OCT.

As shown in fig. 15, 2008.1.15 review the fluorescence contrast: the yellow spot of the left eye is stained with 1PD fluorescence in the early stage, and is also stained with middle dotted fluorescence (pigment disorder) in the later stage. And (4) conclusion: left eye macular degeneration.

As shown in fig. 16, 2008.3.13 reviews OCT. Macular bleeding is seen again, and no further bleeding is seen afterwards.

As shown in fig. 17, 2008.10.16 review OCT.

As shown in fig. 18, 2008.11.27 review OCT.

As shown in fig. 19, 2009.1.9 review OCT.

As shown in fig. 20, 2009.9.28 review OCT. The left eye nerve is high reflection lump on the upper and lower skin, and the omentum edema is not obvious.

As shown in fig. 21, 2010.3.15 review the fluorescence contrast: the retinal arteriovenous filling and regression time of the left eye is basically normal, the early macula is stained by fluorescence (organization) in a 1PD range, the boundary is clear, the middle part is shielded by fluorescence (pigmentation), the choroidal fluorescence is seen around the optic disc, and the retinal is not obviously abnormal in fluorescence in the later period. Conclusion high myopia, macular degeneration in the left eye.

As shown in fig. 22, 2010.3.25 review OCT. Fusiform hyperreflective dense light bolus under the left eye macula, with the surrounding RPE atrophied (scar.

As shown in fig. 23, 2011.3.30 review OCT. Left macular hyperechoic mass (scar

As shown in FIGS. 24 and 25, 2011.6.14ICGA showed low fluorescence in the early macular region, large fluorescence in the choroid, increased value of fovea, and no significant fluorescence leakage in the late stage. The diagnostic opinion: high myopia macular degeneration, Fuchs spot in the left eye.

As shown in fig. 26, 2011.12.28 review OCT. The left eye has a subretinal hyperreflexia with insignificant edema with localized IS/OS interruption.

As shown in fig. 27, 2012.1.3 review fluorescence imaging: the left eye has atrophy arc of optic papilla, the retinal artery and vein filling time is in a normal range, the yellow spots in the early stage of radiography are seen in choroidal transparent fluorescence and irregular high and low fluorescence, and the irregular high and low fluorescence has no obvious morphological size change along with the time. And (4) checking and concluding: high myopia macular degeneration in the left eye.

As shown in fig. 28, 2012.10.11 review the fluorescence contrast: the retinal artery and vein filling time of the left eye is normal, the peripapillary and the posterior extremely low fluorescence (choroidal atrophy) are seen in the early stage, the macular area is accompanied by low fluorescence pigmentation, and the high fluorescence of the yellow spot (sclera pigmentation) is not obviously leaked in the late stage. And (4) conclusion: high myopia in the left eye, old macular chorioretinopathy.

As shown in fig. 29, the OCT: the left fovea atrophies its lower scar.

As shown in fig. 30, 2012.10.23 review OCT: the supracutaneous hyperreflex mass of the macular region in the left eye, with no apparent edema in the omentum, and CNV scars? RPE layer disorder.

As shown in fig. 31 and 32, 2012.12.5 reviewed ICGA: the filling time of the left eye choroid blood vessels is basically normal, local choroid blood vessels are expanded, an atrophy low fluorescence focus is seen in a macular region, large blood vessels are seen in the macular region, and fluorescence staining is carried out at a late stage of radiography. Left eye OCT: focal IS/OS band loss with RPE elevation, lower high reflection signal. And (4) conclusion: left eye macular degeneration focus.

As shown in fig. 33, 2013.12.4 review OCT: left eye macular fovea hyperreflexia-scar? IS/OS interrupts.

As shown in fig. 34, 2013.12.17 reviews FA: the left eye optic papilla temporal atrophy arc, the retinal artery and vein filling time is in a normal range, the posterior pole part is scattered on the retinal pigment epithelium to atrophy and see the choroidal great vessel shadow, the macular macula in the arterial phase is mottled and highly fluorescent, as time goes on, the mottled and highly fluorescent spot is slightly enhanced but has no leakage, the fluorescent light in the later period of radiography is weakened, the boundary is clear, and no obvious morphological size change exists. And (4) conclusion: high myopia macular degeneration in the left eye.

The patient insists on taking the medicine every day from the first visit to the present, and the dosage is never reduced. At present, the vision of the patient wearing the self-glasses is 0 and 4, the vision of the patient is not improved after the self-glasses are used, the myopia is 1.5, and the condition of the eyeground is stable and has no bleeding. (show effect)

According to incomplete statistics, the traditional Chinese medicine composition is used for treating 183 eyes 230, wherein 69 eyes with macular degeneration are 101, 44 eyes with retinal vein occlusion are 45, 29 eyes with diabetic retinopathy are 42, 38 eyes with vitreous hemorrhage are 38, and other hemorrhagic eye diseases such as hypertensive retinal arteriosclerosis III grade, intrabulbar hemorrhage caused by eye trauma, outer exudative retinopathy and the like are 3 eyes 4.

The vision, fundus oculi change and special examination change of the patient are observed, and based on the changes, the front and back comparison is made to judge the effect. The effects are divided into 4 types:

1. the effect is shown: the vision is improved by two or more rows, the eyeground pathological changes are obviously improved or resolved, such as most of hemorrhage, exudation and edema are absorbed or resolved, and the special examination of ophthalmology is improved.

2. The method has the following advantages: the vision is improved one row, the eyeground pathological changes are improved, such as hemorrhage, exudation and edema are absorbed earlier, and the special examination of ophthalmology is improved.

3. And (3) stabilizing: the vision is improved or unchanged, the fundus oculi pathological changes better or unchanged, and the special examination and treatment before and after the ophthalmology is not obviously changed into the stability. In this context, only patients with macular degeneration and diabetic retinopathy have a stable standard of judgment, and the standard of judgment that his hemorrhagic ocular disease is stable is cancelled.

4. And (4) invalidation: no improvement or decline in vision was observed, and ocular fundus lesions and special ophthalmic examinations were considered ineffective in the former case.

In the above 183 cases of 230 eyes treatment, the significant effect was 123 eyes, the effective effect was 49 eyes, the stability was 44 eyes, and the ineffective effect was 14 eyes. The statistical effective rate is as follows: has 172 eyes with obvious and effective effect, and the effective rate is 75 percent.

The above description is only a preferred embodiment of the present invention, and the protection scope of the present invention is not limited to the above embodiments, and all technical solutions belonging to the idea of the present invention belong to the protection scope of the present invention. It should be noted that modifications and embellishments within the scope of the invention may occur to those skilled in the art without departing from the principle of the invention, and are considered to be within the scope of the invention.

Claims

1. The traditional Chinese medicine composition for treating the hemorrhagic eye diseases is characterized by comprising the following traditional Chinese medicines by weight:

2. The traditional Chinese medicine composition for treating hemorrhagic eye diseases according to claim 1, characterized in that the traditional Chinese medicine composition for treating hemorrhagic eye diseases consists of the following traditional Chinese medicines by weight: 20 parts of prepared rhizome of rehmannia, 10 parts of angelica, 10 parts of ligusticum wallichii, 10 parts of red paeony root, 10 parts of safflower, 10 parts of seaweed, 10 parts of kelp, 20 parts of salvia miltiorrhiza, 15 parts of raw grass, 15 parts of raw abalone shell, 20 parts of butterflybush flower, 20 parts of semen cuscutae, 10 parts of rhizoma sparganii, 10 parts of curcuma zedoary, 11-12 parts of peach kernel and 21-22 parts of medlar.

3. The traditional Chinese medicine composition for treating hemorrhagic eye diseases according to claim 1, characterized in that the traditional Chinese medicine composition for treating hemorrhagic eye diseases consists of the following traditional Chinese medicines by weight: 20 parts of prepared rhizome of rehmannia, 10 parts of angelica, 10 parts of ligusticum wallichii, 10 parts of red paeony root, 10 parts of safflower, 10 parts of seaweed, 10 parts of kelp, 20 parts of salvia miltiorrhiza, 15 parts of raw grass, 15 parts of raw abalone shell, 20 parts of butterflybush flower, 20 parts of semen cuscutae, 10 parts of rhizoma sparganii, 10 parts of curcuma zedoary, 11 parts of peach kernel and 21 parts of medlar.

4. The preparation method of the traditional Chinese medicine composition for treating the hemorrhagic eye diseases is characterized by comprising the following steps of: